Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Opus Genetics (IRD) Research & Development (2020 - 2026)

Opus Genetics has reported Research & Development over the past 12 years, most recently at $10.6 million for Q1 2026.

  • Quarterly Research & Development rose 32.99% to $10.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $33.4 million through Mar 2026, up 11.25% year-over-year, with the annual reading at $30.8 million for FY2025, 14.75% up from the prior year.
  • Research & Development was $10.6 million for Q1 2026 at Opus Genetics, up from $10.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $10.6 million in Q1 2026 and troughed at $2.8 million in Q3 2022.
  • The 5-year median for Research & Development is $5.6 million (2023), against an average of $5.9 million.
  • Year-over-year, Research & Development soared 157.07% in 2024 and then decreased 28.65% in 2025.
  • A 5-year view of Research & Development shows it stood at $3.6 million in 2022, then grew by 7.11% to $3.8 million in 2023, then surged by 83.13% to $7.0 million in 2024, then skyrocketed by 48.25% to $10.4 million in 2025, then increased by 1.43% to $10.6 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Research & Development are $10.6 million (Q1 2026), $10.4 million (Q4 2025), and $6.4 million (Q3 2025).